Ann: Completion of Recruitment of ACCENT Trial, page-19

I've been a holder in this stock since it originally listed and you're spot on with your comment regarding the share register.

And even more recently in support of that comment , you would not have to look much further than the Top 20 listing of the new 1 for 2 options exercisable at 17.25 cents on or before 31st October 2027 with Symington Pty Ltd taking up 850,387 and holding .94 of a percentage of them.

Of course Symington Pty Ltd is an entity associated with Alistair Symington and his spouse where Alistair for those who aren't aware is the CEO and Managing director of Blackmores Australia.

Blackmores is in the Health Sciences area of manufacture , branding , and supply of Vitamins and various herbal supplements and was taken out by the large Japanese concern in Kerin Holdings back in August 2023 for $1.2 billion.

And it should be no secret that Kerin's obvious intentions to diversify itself from its traditional Alcoholic and Nonb - Alcoholic beverages business into Health Sciences and has many partnerships in place with some very reputable Pharma Companies through its subsidiary Kyowa Kerin . To mention just a few name , you see them partnered with AstraZeneca , Novartis Genentech, Bristol Myers Squibb , Aveo Oncology , AMGEN ,Ono Pharmaceutical , and Bridge Bio.

They're involved in the delivery of proper drugs too . For example , back in 2018 , they partnered with GSK for the drug Daprodustat which was for the treatment of Chronic Kidney Disease. So they collaborated with GSK in November 2018 , put the drug to submission in Japan in August 2019 , and announced the approval of the drug in June 2020 ....just to give you an idea of that timeline. They then launch the GlaxcoSmithKline drug which goes by its name Duvroq ( in Japan its Daprodustat ) in August 2202 ..., just 2 months after its approval.

And its interesting as well that this drug which they have commercialised in collaboration with GSK is also a very complex HIF-PH Inhibitor which does amazing things with respect to the bodies Iron HIF complex and the production of red blood cells and the interaction with the iron levels to the bone marrow.

Lots pluses and additional benefits of this drug when applied to uses for other treatments and conditions.

So I could see a strong potential link through this particular CEO's stake in Amplia and his connections to the Kerin owned Blackmores Australia.

There are other connections of interest with Amplia as well ....but we don't have to get into them all right now.

I just wanted to pop in and add a response to your post.